EUCTR2012-005314-19-EE进行中（未招募）1 期
A phase III, randomized, open-label, multicenter clinical trial to assess the immunogenicity and safety of GSK Biologicals’ Herpes Zoster vaccine GSK1437173A when co-administered with Pneumovax 23 in adults aged 50 years and older. - ZOSTER-035
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 864
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
- •A male or female aged 50 years or older at the time of the first vaccination with the study vaccine(s).
- •Written informed consent obtained from the subject.
- •Female subjects of non-childbearing potential may be enrolled in the study.
- •-Non-childbearing potential is defined as pre-menarche, current tubal ligation, hysterectomy, ovariectomy or post-menopause.
- •Female subjects of childbearing potential may be enrolled in the study, if the subject:
- •-has practiced adequate contraception for 30 days prior to vaccination, and
- •-has a negative pregnancy test on the day of vaccination, and
- •-has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 486
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 378
排除标准
- •Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period.
- •Chronic administration (defined as more than 14 consecutive days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose (for corticosteroids, this will mean prednisone > or equal 20 mg/day, or equivalent). A prednisone dose of < 20 mg/day is allowed. Inhaled, topical and intra-articular corticosteroids are allowed.
- •Administration or planned administration of a vaccine not foreseen by the study protocol within the period starting 30 days before the first dose of study vaccine(s) and ending 30 days after the last dose of study vaccine. This includes any type of vaccine such as (but not limited to) live, inactivated and subunit vaccines (e.g., inactivated and subunit influenza vaccines and pneumococcal vaccines).
- •Administration of long-acting immune-modifying drugs (e.g. infliximab) within six months prior to the first vaccine dose or expected administration at any time during the study period.
- •Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product (pharmaceutical product or device).
- •Previous vaccination against VZV or HZ and/or planned administration during the study of an HZ or VZV vaccine (including an investigational or non-registered vaccine) other than the study vaccine.
- •History of HZ.
- •History of documented pneumococcal infection within 5 previous years.
- •Prior receipt of any pneumococcal vaccine or planned use of this vaccine during the study period, other than the study vaccine.
- •Any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease (e.g., malignancy, human immunodeficiency virus [HIV] infection) or immunosuppressive/cytotoxic therapy (e.g., medications used during cancer chemotherapy, organ transplantation or to treat autoimmune disorders).
- •History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccines.
- •Acute disease and/or fever at the time of enrolment.
- •-Fever is defined as temperature > or equal 37.5°C /99.5°F by oral route. The preferred route for recording temperature in this study will be oral.
- •-Subjects with a minor illness (such as mild diarrhea, mild upper respiratory infection) without fever may, be enrolled at the discretion of the investigator.
- •Administration of immunoglobulins and/or any blood products within the 3 months preceding the first dose of study vaccine or planned administration during the study period.
- •Pregnant or lactating female.
- •Female planning to become pregnant or planning to discontinue contraceptive precautions before 2 months after the last dose of study vaccine.
- •Any condition which, in the opinion of the investigator, prevents the subject from participating in the study.
- •Any condition which, in the judgment of the investigator, would make intramuscular (IM) injection unsafe.
研究者
相似试验
进行中（未招募）
不适用
Immunogenicity and safety study of GSK Biologicals’ Herpes Zoster vaccine GSK1437173A when co-administered with GSK Biologicals’ seasonal influenza vaccine GSK2321138A in adults aged 50 years and older.Healthy volunteers (Prevention of Herpes Zoster [HZ] and related complications in adults = 50 years of age [YOA ] and immunocompromised adults = 18 YOA.)MedDRA version: 17.1Level: PTClassification code 10019974Term: Herpes zosterSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 17.1Level: HLTClassification code 10019972Term: Herpes viral infectionsSystem Organ Class: 10021881 - Infections and infestationsEUCTR2013-000372-15-DEGlaxoSmithKline Biologicals828
进行中（未招募）
不适用
A phase III, randomized, open-label, multicenter study comparing GW572016 and Capecitabile (Xeloda) versus Capecitabile in women with refractory advanced or metastatic breast cancer.EUCTR2004-001456-36-ITGLAXO SMITHKLINE372
进行中（未招募）
1 期
Multicenter study to evaluate the effect and safety of Ivabradine compared to Digoxin in the control of heart rate in patients with permanent atrial fibrillation.Heart rate control in patients with chronic atrial fibrillation.MedDRA version: 20.0Level: LLTClassification code 10071668Term: Permanent atrial fibrillationSystem Organ Class: 100000004849EUCTR2018-001936-23-ESDr. Adolfo Fontenla Cerezuela
进行中（未招募）
不适用
Immunogenicity and safety of GlaxoSmithKline Biologicals’ DTPa-IPV/Hib (Infanrix™-IPV+Hib) vaccine in healthy Korean infants.Primary immunization of healthy infants in the first year of life against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b (Hib) diseases.EUCTR2012-004137-16-Outside-EU/EEAGlaxoSmithKline Biologicals454
进行中（未招募）
3 期
A research study of an investigational drug delivery system for adults with high-risk non-muscle invasive bladder cancerRecurrent high-risk non-muscle-invasive bladder cancerCancerISRCTN72352492Janssen-Cilag International NV250